Pediatrics

NVK002 atropine 0.01% (Vyluma Inc.) “meaningfully slowed” myopia progression in myopic pediatric patients over a 36-month period.

The Type A meeting addressed questions the FDA had about the late-stage product candidate

Low birth weight, blood transfusion, necrotising enterocolitis, bronchopulmonary dysplasia and antenatal steroid and surfactant therapies are among the factors that affect the development of ROP.

Data from the trial found that MyopiaX proved clinically safe and tolerable, in addition to showing clinical effect on the rate of myopia progression.

The Early Detection of Vision Impairment in Children (EDVI) Act would establish the first federal program to address children’s vision and eye health.

New research findings presented at this year's ARVO meeting compare two groups of paediatric patients in Nepal

Researchers examined disparities in service coverage of pediatric ophthalmologists and pediatric optometrists in relation to patient demographics to cast a light on at-risk populations and provide data for future decisions.

Early keratoconus screening advocated

Evaluating injections of anti-VEGF drugs into the intra-anterior chamber may be a viable alternative, but further study is required.

Siloam Vision and Orbis team up to develop infrastructure to save the vision of premature infants.

According to the company, MicroPine, currently in late phase III for pediatric progressive myopia, will complement Eyenovia’s commercial-stage asset, Mydcombi, as well as its pre-PDUFA candidate, APP13007.

The first step in management is increasing the time spent outside

Analysis showed low-dose, preservative-free formulation of atropine is effective in slowing progression in children aged 3 to 17, living in the US and European Union.

According to data presented at the American Academy of Ophthalmology annual meeting in San Francisco, a study of children with cell disease finds 1 in 3 had retinopathy.

The collaboration, fueled by a $5 million donation from Knights Templar Eye Foundation (KTEF), will introduce a free and open VR simulation program for ophthalmologists and trainees worldwide.

OCT and OCTA imaging were especially valuable in this patient population because the images extended the current definition of sickle cell retinopathy.

The FDA has granted temporary discretion to import erythromycin ophthalmic ointment for the treatment of newborns.

Polish researchers found positive bacterial cultures in premature infants correlated with severe retinopathy of prematurity (ROP), suggesting a potential prognostic marker for early ROP development.

NVK002 is currently under FDA review, with a PDUFA date scheduled for January 31, 2024.

The MyopiaX-1 trial studies MyopiaX, a smartphone application that aims to slow the progression of myopia, or nearsightedness, in children and adolescents.

Efficacy of treatment option is also confirmed in pediatric population in India.

According to the companies, the partnership will roll out a proprietary system that has earned FDA breakthrough designation, one of the few ophthalmic devices to achieve this status in almost a decade.

Research from Orbis International analyzes the overall wellbeing of children with common childhood vision problems.

The 6-month-old boy’s dark brown eyes turned deep blue after he was treated for COVID with favipiravir.

Henriquez pointed out that waiting for keratoconic progression runs the inherent risk that keratoconus will progress rapidly and affect the planned initial treatment protocol.